Clinical Trial Update: Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping

View source ↗

Summary

This clinical trial update describes the ongoing managed access program for Del-zota in participants with Duchenne muscular dystrophy mutations amenable to exon…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• Del-zota

Snippet

Sponsor: Avidity Biosciences, Inc. | Conditions: Muscular Disorders, Atrophic, Muscular Diseases | Status: AVAILABLE